With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.51094-17-8,4,4′,4”,4”’-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis-Phenol,as a common compound, the synthetic route is as follows.,51094-17-8
COMPOUND 1; 5,10,15,20-tetralds-[4-(3-Trimeth34ammonio-propyloxy)-phenyl]- porphyrin tetrachloride; To a vigorously-stirred suspension of 5,10,15,20-tetrakis-(4-hydroxy- phenyl)-porphyrin (50 mg, 0.07 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (20 mL), a solution of (l-bromopropyl)-trimethylammonium bromide (0.27 g, 1.05 mmol) in DMF (5 mL) is added dropwise at 5O0C during 30 mins. The mixture is stirred at 5O0C for 15 h. After removal of DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing with methanol (1 L), the pad is eluted with acetic acid. After evaporation of solvent from the eluate, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH20 eluting with n- butanol: water: acetic acid (4:5:1, by vol., upper phase). The recovered material is dissolved in the minimum volume of methanol and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 40O5 chloride form). The recovered tetrachloride salt is dried under high vacuum and obtained as a violet solid. 1H-NMR: deltaH (300MHz, CD3OD): 2.35-2.50 (bs. 8 H), 3.25-3.35 (bs, 36 H), 3.65- 3.75 (bs, 8 H), 4.35 (m, 8 H), 7.30, 8.10 (2 x d, 3J 8.5 Hz, 16 H), 8.80- 9.00 (bs, 8 H).
51094-17-8 4,4′,4”,4”’-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis-Phenol 135438030, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI